Archives

  • 2018-07
  • 2018-10
  • 2018-11
  • 2019-04
  • 2019-05
  • 2019-06
  • 2019-07
  • The Eph ephrin signaling system has the

    2019-07-10

    The Eph–ephrin signaling system has the ability to elicit bidirectional signaling, classical forward signaling by both Eph receptor via its intrinsic tyrosine kinase activity and reverse signaling by the transmembrane ephrin ligand via its cytoplasmic domain [38], [39]. Thus when EphB4 binds with ephrinB2, it activates the receptors and the Annexin V-Cy3 Apoptosis Kit expressing ephrinB also demonstrate increased intracellular signaling due to the attachment of receptors and all known ephrin ligands to the plasma membrane [6], [39]. When EphB4 is activated multiple tyrosine sites are phosphorylated and the kinase domains are activated, though soluble forms of ephrinB2 are unable to activate their receptors [6], [40]. In our study, coexpression of EphB4 and ephrinB2 might work on tumor advancement via autocrine stimulation in uterine cervical cancer cells. The coexpression of EphB and ephrinB on the same cells may suggest that tumor–tumor cell contact could autonomously activate the EphB/ephrinB system, thus promoting tumor plasticity through the well described capacity for EphB/ephrinB signals to induce cell-to-cell repulsion [14], [33], [41]. When EphB4 co-expresses with ephrinB2, it may suggest that high EphB4 expression precedes ephrinB2 overexpression, which might explain why ephrinB2 expression is most highly correlated with tumor advancement.
    Conflict of interest statement
    Acknowledgment